Biological and Radiological Responses to Oral Etidronate and Tiludronate in Paget's Disease of Bone
作者： J.P. Devogelaer , J. Malghem , P. Stasse , C.Nagant De Deuxchaisnes
DOI: 10.1016/S8756-3282(96)00368-7
关键词:
摘要: Paget's disease of bone is characterized by a high turnover. Therefore, antiresorbing agents such as bisphosphonates are clearly indicated. However, they accumulate in the pagetic lesions, could produce some focal defects mineralization. In double-blind study, we have had opportunity to compare effects tiludronate and etidronate (both at fixed dose 400 mg/day orally) on radiological changes 12 patients suffering from bone. After breaking code, good agreement was observed between evaluations applied therapy: All positive balances were group, except for three questionable densifications negative group. This confirms our previous experience with when X-ray films lesions followed sequentially during therapy.
elsevier.com
sci-hub.se 参考文章(10)
C. Roux, C. Gennari, J. Farrerons, J. P. Devogelaer, H. Mulder, H. P. Kruse, C. Picot, L. Titeux, J. Y. Reginster, M. Dougados, Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis & Rheumatism. ,vol. 38, pp. 851- 858 ,(1995) , 10.1002/ART.1780380620
B. MALDAGUE, J. MALGHEM, Dynamic radiologic patterns of Paget's disease of bone. Clinical Orthopaedics and Related Research. ,vol. 217, pp. 126- 151 ,(1987) , 10.1097/00003086-198704000-00012
C.Nagantde Deuxchaisnes, J.P. Dufour, J.P. Devogelaer, J.P. Huaux, W. Esselinckx, ETIDRONATE AND THE RISK OF FRACTURES The Lancet. ,vol. 2, pp. 610- 611 ,(1985) , 10.1016/S0140-6736(85)90607-5
D. Liens, P.D. Delmas, Pj Meunier, Long-term effects of intravenous pamidronate in fibrous dysplasia of bone The Lancet. ,vol. 343, pp. 953- 954 ,(1994) , 10.1016/S0140-6736(94)90069-8
Sunil J. Wimalawansa, Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study The American Journal of Medicine. ,vol. 99, pp. 36- 42 ,(1995) , 10.1016/S0002-9343(99)80102-8
C. Alexandre, P.J. Meunier, C. Edouard, R.A. Khairi, C.C. Johnston, Effects of ethane-1 hydroxy-1, 1-Diphosphonate (5 mg/kg/day dose) onquantitative bone histology in paget's disease of bone Metabolic Bone Disease and Related Research. ,vol. 3, pp. 309- 315 ,(1981) , 10.1016/0221-8747(81)90047-3
C. De Nagant Deuxchaisnes, B. Maldague, J. Malghem, J. P. Devogelaer, J. P. Huaux, C. Rombouts-Lindemans, The Action of the Main Therapeutic Regimes On Pagets-disease of Bone, With a Note On the Effect of Vitamin-d Deficiency Arthritis & Rheumatism. ,vol. 23, pp. 1215- 1234 ,(1980) , 10.1002/ART.1780231020
B.B. Adamson, J. Byars, B.F. Boyce, S.J. Gallacher, S.H. Ralston, I.T. Boyle, B.F. Boyce, Mineralisation defects with pamidronate therapy for Paget's disease The Lancet. ,vol. 342, pp. 1459- 1460 ,(1993) , 10.1016/0140-6736(93)92935-M
R.M. Neer, Skeletal safety of tiludronate. Bone. ,vol. 17, ,(1995) , 10.1016/8756-3282(95)00343-7
JOHN A. KANIS, RICHARD E. S. GRAY, Long-term follow-up observations on treatment in Paget's disease of bone. Clinical Orthopaedics and Related Research. pp. 99- 125 ,(1987) , 10.1097/00003086-198704000-00011